Richard Yeh

Richard Yeh is currently Independent Non-Executive Director at Immvira Bioscience, Inc. since 2025, Lead Independent Non-Executive Director at ADICON Holdings Ltd. since 2026, and Independent Non-Executive Director at Medlive Technology Co., Ltd. since 2021.
Former roles include Director, Chief Operating & Financial Officer at NovaBridge Biosciences from 2022 to 2024; CFO, Director & Head-Strategic Operations at Abbisko Therapeutics Co., Ltd. from 2021 to 2022; CFO, Executive Director & Head-Operations at Abbisko Cayman Ltd. from 2020 to 2022; Chief Financial Officer at CStone Pharmaceuticals Co. Ltd. from 2018 to 2020; Research Associate at Canaccord Adams, Inc. from 2003 to 2004; Research Analyst at Needham & Co. LLC.
from 2005 to 2007; and other positions including Director at I-MAB Biopharma Co., Ltd. and Tasly Pharmaceutical Group Co., Ltd., Research Associate at Amgen, Inc., Research Analyst at Citigroup Global Markets, Inc. (Broker), Corporate Development Manager at GenoSpectra, Inc., Analyst at Wyeth Pharmaceuticals LLC, Head of China Healthcare Research at Citigroup Global Markets Asia Ltd., and Analyst at Goldman Sachs (Asia) LLC.
Education includes an MBA from Cornell University in 2002, graduate degree from the University of Toronto in 1995, and undergraduate degree from the University of Manitoba in 1993.